Jiaqi Cao

发表

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer.

Weitao Fu, Lingfeng Chen, Lulu Zheng, 2023, Journal of medicinal chemistry.

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

Lin Ma, Mingwan Zhang, Ying Xu, 2024, Journal of medicinal chemistry.